Category: GLP-1s

New York City-based online, direct-to-consumer healthcare company Ro has launched a tool to report and track GLP-1 drug shortages across the U.S., it announced May 29.

Novo Nordisk is contesting Sen. Bernie Sanders’ calls to reduce the list prices of Ozempic and Wegovy in the U.S., Bloomberg reports. 

In a yearslong trial of more than 3,500 participants, Novo Nordisk’s Ozempic and Wegovy slowed the growth of chronic kidney disease and slashed the risk of heart attack, kidney failure, stroke and death. 

Two Eli Lilly manufacturing plants in Indiana are getting a $5.3 billion boost to increase production of Zepbound and Mounjaro, the company said May 24. 

GLP-1s, a popular class of weight loss and diabetes drugs, can hinder the safety of a common gastroenterology procedure, according to a study published in Gastrointestinal Endoscopy.  

GLP-1 drugs’ recent blockbuster appeal has already changed the way providers and pharmacists are doing their jobs, but the American Hospital Association says their appeal could shift other aspects of hospital operations too.

A majority of patients taking weight loss drugs discontinue use of their medication before reaching a clinically meaningful health benefit, according to new research published May 21 by the Blue Cross Blue Shield Association.

A $350 genetic test developed by researchers at Mayo Clinic in Rochester, Minn., and subsequently licensed to Phenomic Sciences, seeks to assign risk scores to patients regarding their likelihood of responding well to GLP-1 anti-obesity drugs like Wego…

Weight loss drugs have the potential to bankrupt the U.S. healthcare system, according to a May 15 report from Sen. Bernie Sanders’s office.

Novo Nordisk is investigating the potential of Ozempic, Wegovy’s active ingredient and two other drug candidates as treatments for alcohol-related liver disease.